User login
Key clinical point: In patients with migraine, an increase in monthly headache days (MHD) adversely impacts health-related quality of life (HRQoL) measured by the Migraine-Specific Quality-of-Life Questionnaire (MSQ), with the impact being partially mediated by depression, allodynia, and anxiety.
Major finding: For every 1-day increase in the MHD, the scores for MSQ’s Role Function-Restrictive, Role Function-Preventive, and Emotional Function parameters worsened by 0.92, 0.60, and 1.23 points, respectively (all P < .001). Depression, allodynia, and anxiety mediated 15.2%-24.3%, 9.6%-16.1%, and 2.3%-6.0%, respectively, of the total observed effects of MHD on the HRQoL.
Study details: Findings are from a post hoc analysis of the CaMEO study including 12,715 patients with migraine who completed the Core and Comorbidities/Endophenotypes modules.
Disclosures: This study was funded by Allergan (prior to its acquisition by AbbVie). B Dabruzzo declared being an employee of AbbVie and may own its stocks. The other authors declared ties with various sources, including AbbVie.
Source: Lipton RB et al. Impact of monthly headache days on migraine-related quality of life: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. Headache. 2023 (Oct 5). doi: 10.1111/head.14629
Key clinical point: In patients with migraine, an increase in monthly headache days (MHD) adversely impacts health-related quality of life (HRQoL) measured by the Migraine-Specific Quality-of-Life Questionnaire (MSQ), with the impact being partially mediated by depression, allodynia, and anxiety.
Major finding: For every 1-day increase in the MHD, the scores for MSQ’s Role Function-Restrictive, Role Function-Preventive, and Emotional Function parameters worsened by 0.92, 0.60, and 1.23 points, respectively (all P < .001). Depression, allodynia, and anxiety mediated 15.2%-24.3%, 9.6%-16.1%, and 2.3%-6.0%, respectively, of the total observed effects of MHD on the HRQoL.
Study details: Findings are from a post hoc analysis of the CaMEO study including 12,715 patients with migraine who completed the Core and Comorbidities/Endophenotypes modules.
Disclosures: This study was funded by Allergan (prior to its acquisition by AbbVie). B Dabruzzo declared being an employee of AbbVie and may own its stocks. The other authors declared ties with various sources, including AbbVie.
Source: Lipton RB et al. Impact of monthly headache days on migraine-related quality of life: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. Headache. 2023 (Oct 5). doi: 10.1111/head.14629
Key clinical point: In patients with migraine, an increase in monthly headache days (MHD) adversely impacts health-related quality of life (HRQoL) measured by the Migraine-Specific Quality-of-Life Questionnaire (MSQ), with the impact being partially mediated by depression, allodynia, and anxiety.
Major finding: For every 1-day increase in the MHD, the scores for MSQ’s Role Function-Restrictive, Role Function-Preventive, and Emotional Function parameters worsened by 0.92, 0.60, and 1.23 points, respectively (all P < .001). Depression, allodynia, and anxiety mediated 15.2%-24.3%, 9.6%-16.1%, and 2.3%-6.0%, respectively, of the total observed effects of MHD on the HRQoL.
Study details: Findings are from a post hoc analysis of the CaMEO study including 12,715 patients with migraine who completed the Core and Comorbidities/Endophenotypes modules.
Disclosures: This study was funded by Allergan (prior to its acquisition by AbbVie). B Dabruzzo declared being an employee of AbbVie and may own its stocks. The other authors declared ties with various sources, including AbbVie.
Source: Lipton RB et al. Impact of monthly headache days on migraine-related quality of life: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. Headache. 2023 (Oct 5). doi: 10.1111/head.14629